FDA Approves Rasonque for Pancreatic Cancer: When It’s Available and Cost

The FDA approved Rasonque for pancreatic cancer. Here is when the drug will be available, who qualifies and what it costs.

Pancreatic cancer has been notoriously difficult to target and treat. wildpixel/iStock via Getty Images Plus For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of

The Food and Drug Administration on Wednesday rubber-stamped a new drug to treat pancreatic cancer and substantially extend the lives of patients. The drug, daraxonrasib, is produced by Revolution Medicines and was approved for individuals with metastatic pancreatic cancer who did not see success with chemotherapy. Doc

The US Food and Drug Administration announced its approval for a drug that could double the survival time of some patients for a type of cancer that has, historically, been difficult to treat.

The US Food and Drug Administration announced its approval for a drug that could double the survival time of some patients for a type of cancer that has, historically, been difficult to treat.

On Wednesday, the U.S. Food and Drug Administration announced its approval of Rasonque, a new treatment option for people with pancreatic cancer.

The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial

The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.

The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer.  The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Ra

Pancreatic cancer is among the deadliest forms, largely because detection is difficult before malignancy spreads to other organs

WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer.

Patients taking the drug nearly doubled their survival time, with fewer severe side effects, in a study that randomly assigned them to receive the experimental treatment or more chemotherapy.

The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer.

Daraxonrasib made headlines earlier this year when former US Sen. Ben Sasse, R-Neb., shared details about his experience with the drug — which left his skin bloody and “bubbling” but is giving him more time with his family.

WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called dara

Pancreatic cancer is considered one of the hardest to treat and most serious cancers

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer

FDA approves landmark pancreatic cancer drug that’s shown to improve survival  AP News

FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque  Forbes

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease  WSJ

The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.